Deutsche Bank initiated coverage of Zealand Pharma with a Hold rating and DKK 815 price target The firm says the stock’s valuation already reflects much of optimism for the opportunity around the company’s amylin asset petrelintide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF: